#hims--hers

[ follow ]
#stock-market #fda #telehealth #bank-of-america #regulatory-action #glp-1-weight-loss-market #patent-lawsuit
Healthcare
from24/7 Wall St.
1 week ago

BofA Raises Hims & Hers Target to $25 as FDA Takes a Step Toward Wellness Peptides: Is a New Revenue Boom Coming?

Bank of America raised Hims & Hers' price target to $25, citing FDA's evaluation of wellness peptides as a potential revenue opportunity.
Healthcare
from24/7 Wall St.
2 months ago

Wall Street Sees 84% Upside in Hims & Hers (HIMS) Despite This Month's 48% Selloff

Hims & Hers plunged ~48% after FDA action and a patent lawsuit, yet analysts project substantial upside based on subscriber growth and revenue strength.
fromFortune
2 months ago

Hims & Hers scraps copycat Wegovy weight-loss pill after probe | Fortune

After having "constructive conversations with stakeholders," Hims decided to stop offering the treatment, the company said in a post on X Saturday.
Health
from24/7 Wall St.
8 months ago

Live: Will Hims & Hers (HIMS) Rally After Q2 Earnings After the Bell?

Hims & Hers has seen stock performance boosted by high demand for personalized health services and early traction in the weight loss category. Revenue is estimated to reach $278.66 million for Q2, with a projected full-year revenue of $1.14 billion, reflecting nearly 40% growth compared to the previous year.
Health
Health
fromInsideHook
9 months ago

Compounding Breaks Up Novo Nordisk-Hims & Hers Partnership

Compounded alternatives to GLP-1 drugs raise safety concerns and regulatory scrutiny.
NYC startup
from24/7 Wall St.
10 months ago

S&P 500 (NYSEARCA: SPY) Live: Markets Turn Higher in Face of Heightened Mideast Tensions

Market gains follow U.S. strikes on Iran, but stock performances vary significantly among companies.
[ Load more ]